Regenerative Medical Technology Group Inc (RMTG) Stock Analysis
Verdict: AVOID
Surging top-line sales cannot offset severe working capital distress (-$35.6M deficit) and massive negative equity, signaling severe dilution risk.
Investment score: 17/100
Analysis as of
Is Regenerative Medical Technology Group Inc stock worth reviewing? AI model thesis
The AI model views RMTG as a high-risk microcap with extreme financial distress. Surging revenue ($5.10M in 2025) is overshadowed by -$34.75M in total equity and a current ratio of 0.041.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Regenerative Medical Technology Group Inc opportunities and risks
What speaks for RMTG
- Revenue expanded 73.79% to $5.10M in 2025 from $2.41M in 2023.
What speaks against RMTG
- Working capital deficit stands at -$35.60M, reflected by a current ratio of 0.041 ($36.82M current liabilities vs $1.22M current assets).
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RMTG | n/a | 0.1x | 10.8x | 58.6% | -101.2% | -49.2% |
| BWTL | 881.0x | 0.4x | 10.2x | 45.5% | 0.0% | -2.4% |
| LESL | n/a | 0.0x | n/a | 33.7% | -21.2% | -127.7% |
| EATR | n/a | 0.0x | n/a | 0.0% | 0.0% | 12.1% |
| RTON | n/a | 1.5x | n/a | 54.3% | -15.7% | -5.5% |
| Peer median | n/a | 0.2x | n/a | 39.6% | -7.8% | -3.9% |
Frequently asked questions about Regenerative Medical Technology Group Inc (RMTG)
Is RMTG stock a good investment?
The cached TradeMates AI model rates Regenerative Medical Technology Group Inc as AVOID with an investment score of 17/100. The AI model views RMTG as a high-risk microcap with extreme financial distress. Surging revenue ($5.10M in 2025) is overshadowed by -$34.75M in total equity and a current ratio of 0.041. This is algorithmic model output, not personal investment advice.
Is RMTG stock a buy?
The TradeMates model verdict for RMTG is AVOID with an investment score of 17/100. Treat this as a model signal to review, not a personal buy recommendation.